MAP2K2 and cancer: The miR-93 targets programmed cell death 1 ligand 2 (PDCD1LG2, also known as PD-L2), which is related to cancer immunotherapy, and G-protein coupled receptor 137C (GPR137C), and mitogen-activated protein kinase kinase kinase 2 (MAP3K2, also known as MEKK2) in the RAS-MAPK signaling (S1 Table).